4. Retrospective A 50-Gene Intrinsic Subtype Population: FFPE samples from premenopausal primary breast 2012 cohort study Classifier for Prognosis and cancer, stage I to III, ER +ve or node +/-ve –ve, Prediction of Benefit from Adjuvant Prognostic Purpose: to evaluate prognostic and predictive significance of Tamoxifen level III-3 intrinsic subtypes identified by PAM50 compared to an IHC panel Chia et al Results: PAM50 subtype was prognostic for disease-free survival (p = 0.0003) and overall survival (p = 0.0002), whereas the IHC panel was not. Luminal subtypes were predictive of a tamoxifen benefit. The trend was the same irrespective of hormone status. 5. Retrospective Molecular subtype and Population: Fine needle aspirates from 149 patients with distant 2014 cohort study characteristics of breast cancer breast cancer relapse, ER +ve or who were enrolled in the –ve, metastases as assessed by gene TEX trial Prognostic expression significantly influence level III-3 Purpose: To determine whether tumour characteristics and patient post-relapse survival subtypes in breast cancer confer clinically relevant prognostic Tobin et al information TEX trial: NCT01433614 Results: Subtyping provided statistically significant post-relapse survival information (basal-like HR 3.7 [95% CI 1.3–10.9] and HER2-enriched HR 4.4 [95% CI 1.5–12.8] subtypes compared with the luminal A subtype).
4. Retrospective cohort study Prognostic level III-3 A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen Chia et al Population: FFPE samples from premenopausal primary breast cancer, stage I to III, ER +ve or –ve, node +/-ve Purpose: to evaluate prognostic and predictive significance of intrinsic subtypes identified by PAM50 compared to an IHC panel Results: PAM50 subtype was prognostic for disease-free survival (p = 0.0003) and overall survival (p = 0.0002), whereas the IHC panel was not. Luminal subtypes were predictive of a tamoxifen benefit. The trend was the same irrespective of hormone status. 2012 5. Retrospective cohort study Prognostic level III-3 Molecular subtype and characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival Tobin et al TEX trial: NCT01433614 Population: Fine needle aspirates from 149 patients with distant breast cancer relapse, ER +ve or –ve, who were enrolled in the TEX trial Purpose: To determine whether tumour characteristics and subtypes in breast cancer confer clinically relevant prognostic information Results: Subtyping provided statistically significant post-relapse survival information (basal-like HR 3.7 [95% CI 1.3–10.9] and HER2-enriched HR 4.4 [95% CI 1.5–12.8] subtypes compared with the luminal A subtype). 2014